Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for STOK

Stock Name	Stoke Therapeutics Inc
Ticker	STOK(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US86150R1077
LEI	549300RD25SS2DIJHJ67

Show aggregate STOK holdings

News associated with STOK

Notable Wednesday Option Activity: AAPL, STOK, Z: Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Apple Inc (Symbol: AAPL), where a total volume of 543,181 contracts has been traded thus far today, a contract volume which is representative of approximately 54 - 2025-09-17 16:17:22
7 Biotech Stocks Trading At 52-Week Highs - Can The Rally Continue?: (RTTNews) - Patience is a virtue - important in all aspects of life, and especially crucial when it comes to investing. As trading expert Steve Burns once said, "Much of our trading comes down to a battle between our patience and our impulses." - 2025-09-15 03:55:16
Analysts Set Stoke Therapeutics, Inc. (NASDAQ:STOK) PT at $25.57: Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) has earned an average rating of “Buy” from the nine ratings firms that are covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among […] - 2025-08-22 03:12:53
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up on Better-Than-Expected Earnings: Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report)’s share price gapped up before the market opened on Wednesday following a better than expected earnings announcement. The stock had previously closed at $13.53, but opened at $14.89. Stoke Therapeutics shares last traded at $15.14, with a volume of 236,029 shares changing hands. The company reported ($0.40) […] - 2025-08-15 02:34:48
40,181 Shares in Stoke Therapeutics, Inc. (NASDAQ:STOK) Acquired by XTX Topco Ltd: XTX Topco Ltd purchased a new stake in Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) during the 1st quarter, HoldingsChannel reports. The fund purchased 40,181 shares of the company’s stock, valued at approximately $267,000. Other large investors have also recently bought and sold shares of the company. RTW Investments LP raised its position in Stoke […] - 2025-08-12 04:30:53
Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $25.80: Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) has received an average recommendation of “Buy” from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price […] - 2025-07-28 02:30:54
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up – Here’s What Happened: Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) shares gapped up prior to trading on Friday . The stock had previously closed at $12.35, but opened at $12.93. Stoke Therapeutics shares last traded at $12.75, with a volume of 96,492 shares traded. Wall Street Analyst Weigh In A number of research analysts have recently weighed […] - 2025-07-20 05:22:59
Alps Advisors Inc. Sells 2,940 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK): Alps Advisors Inc. decreased its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) by 6.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,890 shares of the company’s stock after selling 2,940 shares during the period. Alps Advisors Inc.’s holdings […] - 2025-07-18 05:21:01
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Rating of “Buy” by Brokerages: Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) have been assigned an average recommendation of “Buy” from the seven analysts that are covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average […] - 2025-06-30 02:34:50
Assenagon Asset Management S.A. Cuts Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK): Assenagon Asset Management S.A. lowered its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) by 29.0% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 959,603 shares of the company’s stock after selling 391,322 shares during the period. Assenagon Asset Management S.A.’s holdings in Stoke Therapeutics were worth $6,381,000 as of […] - 2025-06-15 05:44:52
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by BNP Paribas Financial Markets: BNP Paribas Financial Markets decreased its position in Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) by 94.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,422 shares of the company’s stock after selling 71,732 shares during the quarter. BNP Paribas Financial […] - 2025-06-04 05:14:48
Legal & General Group Plc Has $390,000 Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK): Legal & General Group Plc trimmed its position in Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) by 5.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,347 shares of the company’s stock after selling 2,139 shares during the quarter. Legal & General […] - 2025-05-01 04:42:53
Renaissance Technologies LLC Buys Shares of 129,043 Stoke Therapeutics, Inc. (NASDAQ:STOK): Renaissance Technologies LLC purchased a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 129,043 shares of the company’s stock, valued at approximately $1,423,000. Other large investors have […] - 2025-04-29 04:58:53
Stoke Therapeutics (NASDAQ:STOK) Receives “Buy” Rating from Needham & Company LLC: Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Needham & Company LLC in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $22.00 price objective on the stock. Needham & Company LLC’s price objective suggests a potential upside of 237.42% from […] - 2025-04-11 04:46:50
HC Wainwright Reaffirms “Buy” Rating for Stoke Therapeutics (NASDAQ:STOK): Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $47.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 464.23% from the stock’s previous close. HC […] - 2025-03-21 04:25:10
Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Needham & Company LLC: Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Needham & Company LLC in a report released on Tuesday,Benzinga reports. They presently have a $22.00 target price on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 166.34% from the stock’s […] - 2025-03-20 04:44:48
Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $23.00: Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) have earned an average rating of “Buy” from the ten ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy […] - 2025-02-28 04:26:56
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $21.29 Average Target Price from Brokerages: Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) has earned an average recommendation of “Buy” from the ten analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The […] - 2025-02-03 04:24:54

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc STOK holdings

Date	Number of STOK Shares Held	Base Market Value of STOK Shares	Local Market Value of STOK Shares	Change in STOK Shares Held	Change in STOK Base Value	Current Price per STOK Share Held	Previous Price per STOK Share Held
2025-09-29 (Monday)	6,706	USD 165,839	USD 165,839
2025-09-26 (Friday)	6,706	USD 161,883	USD 161,883
2025-09-25 (Thursday)	6,706	USD 153,903	USD 153,903	0	USD 671	USD 22.95	USD 22.85
2025-09-24 (Wednesday)	6,706	USD 153,232	USD 153,232
2025-09-17 (Wednesday)	6,664	USD 151,539	USD 151,539	0	USD -2,799	USD 22.7399	USD 23.16
2025-09-16 (Tuesday)	6,664	USD 154,338	USD 154,338
2025-09-12 (Friday)	6,622	USD 155,352	USD 155,352
2025-09-11 (Thursday)	6,622	USD 158,133	USD 158,133	84	USD 14,362	USD 23.8799	USD 21.9901

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of STOK by Blackrock for IE00B3VWM098

Show aggregate share trades of STOK

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-09-11 BUY 84 23.880* 10.47
2025-08-21 SELL -21 19.680* 10.42 Profit of 219 on sale
2025-07-31 BUY 63 12.850* 10.35
2025-06-30 SELL -42 11.350* 10.10 Profit of 424 on sale
2025-06-25 SELL -21 11.810* 10.06 Profit of 211 on sale
2025-06-20 SELL -42 11.580* 10.03 Profit of 421 on sale
2025-05-23 BUY 21 9.360* 9.92
2025-05-19 SELL -21 9.830* 9.92 Profit of 208 on sale
2025-05-15 SELL -63 9.630* 9.93 Profit of 625 on sale
2025-05-12 SELL -21 9.660* 9.95 Profit of 209 on sale
2025-05-09 SELL -21 9.360* 9.95 Profit of 209 on sale
2025-04-30 SELL -21 9.760* 9.99 Profit of 210 on sale
2025-04-24 SELL -42 9.880* 10.01 Profit of 420 on sale
2025-04-17 SELL -21 7.690* 10.08 Profit of 212 on sale
2025-04-15 SELL -63 7.750* 10.14 Profit of 639 on sale
2025-04-14 SELL -63 7.560* 10.17 Profit of 640 on sale
2025-04-09 SELL -84 6.430* 10.28 Profit of 864 on sale
2025-04-07 SELL -147 6.010* 10.38 Profit of 1,526 on sale
2025-04-04 SELL -210 5.940* 10.43 Profit of 2,191 on sale
2025-03-31 BUY 21 6.650* 10.58
2025-03-19 SELL -42 8.260* 10.87 Profit of 456 on sale
2025-03-14 SELL -126 8.600* 10.95 Profit of 1,380 on sale
2025-03-13 SELL -42 8.110* 10.99 Profit of 462 on sale
2025-03-12 SELL -714 8.520* 11.03 Profit of 7,874 on sale
2025-03-07 SELL -42 8.010* 11.16 Profit of 469 on sale
2025-03-06 SELL -63 8.150* 11.21 Profit of 706 on sale
2025-03-03 SELL -21 7.400* 11.37 Profit of 239 on sale
2025-02-28 SELL -126 7.850* 11.43 Profit of 1,440 on sale
2025-02-26 SELL -21 8.270* 11.54 Profit of 242 on sale
2025-02-25 SELL -63 8.250* 11.60 Profit of 731 on sale
2025-02-18 BUY 105 9.710* 11.89
2025-02-13 BUY 21 10.630* 11.97
2025-02-12 BUY 21 10.260* 12.00
2025-02-11 BUY 63 10.320* 12.04
2025-02-06 BUY 189 12.740* 12.07
2025-01-27 BUY 21 10.570* 12.25
2024-12-30 BUY 105 10.800* 12.42
2024-12-06 BUY 84 13.270* 12.32
2024-12-05 BUY 21 12.570* 12.31
2024-12-04 BUY 105 12.810* 12.29
2024-11-29 BUY 105 12.110* 12.34
2024-11-27 BUY 84 11.910* 12.38
2024-11-26 BUY 21 11.770* 12.41
2024-11-21 BUY 105 11.270* 12.55
2024-11-20 BUY 63 11.310* 12.62
2024-11-18 BUY 252 11.880* 12.73
2024-11-12 BUY 168 13.620* 12.67
2024-11-08 BUY 105 13.880* 12.59
2024-11-07 BUY 315 13.270* 12.53
2024-11-06 BUY 42 13.250* 12.47
2024-10-31 BUY 21 12.360* 12.29
Market high and low price is on the date.

Date	Action	Quantity	Likely Trade Price	Average Price previous trades
2025-09-11	BUY	84	23.880*	10.47
2025-08-21	SELL	-21	19.680*	10.42 Profit of 219 on sale
2025-07-31	BUY	63	12.850*	10.35
2025-06-30	SELL	-42	11.350*	10.10 Profit of 424 on sale
2025-06-25	SELL	-21	11.810*	10.06 Profit of 211 on sale
2025-06-20	SELL	-42	11.580*	10.03 Profit of 421 on sale
2025-05-23	BUY	21	9.360*	9.92
2025-05-19	SELL	-21	9.830*	9.92 Profit of 208 on sale
2025-05-15	SELL	-63	9.630*	9.93 Profit of 625 on sale
2025-05-12	SELL	-21	9.660*	9.95 Profit of 209 on sale
2025-05-09	SELL	-21	9.360*	9.95 Profit of 209 on sale
2025-04-30	SELL	-21	9.760*	9.99 Profit of 210 on sale
2025-04-24	SELL	-42	9.880*	10.01 Profit of 420 on sale
2025-04-17	SELL	-21	7.690*	10.08 Profit of 212 on sale
2025-04-15	SELL	-63	7.750*	10.14 Profit of 639 on sale
2025-04-14	SELL	-63	7.560*	10.17 Profit of 640 on sale
2025-04-09	SELL	-84	6.430*	10.28 Profit of 864 on sale
2025-04-07	SELL	-147	6.010*	10.38 Profit of 1,526 on sale
2025-04-04	SELL	-210	5.940*	10.43 Profit of 2,191 on sale
2025-03-31	BUY	21	6.650*	10.58
2025-03-19	SELL	-42	8.260*	10.87 Profit of 456 on sale
2025-03-14	SELL	-126	8.600*	10.95 Profit of 1,380 on sale
2025-03-13	SELL	-42	8.110*	10.99 Profit of 462 on sale
2025-03-12	SELL	-714	8.520*	11.03 Profit of 7,874 on sale
2025-03-07	SELL	-42	8.010*	11.16 Profit of 469 on sale
2025-03-06	SELL	-63	8.150*	11.21 Profit of 706 on sale
2025-03-03	SELL	-21	7.400*	11.37 Profit of 239 on sale
2025-02-28	SELL	-126	7.850*	11.43 Profit of 1,440 on sale
2025-02-26	SELL	-21	8.270*	11.54 Profit of 242 on sale
2025-02-25	SELL	-63	8.250*	11.60 Profit of 731 on sale
2025-02-18	BUY	105	9.710*	11.89
2025-02-13	BUY	21	10.630*	11.97
2025-02-12	BUY	21	10.260*	12.00
2025-02-11	BUY	63	10.320*	12.04
2025-02-06	BUY	189	12.740*	12.07
2025-01-27	BUY	21	10.570*	12.25
2024-12-30	BUY	105	10.800*	12.42
2024-12-06	BUY	84	13.270*	12.32
2024-12-05	BUY	21	12.570*	12.31
2024-12-04	BUY	105	12.810*	12.29
2024-11-29	BUY	105	12.110*	12.34
2024-11-27	BUY	84	11.910*	12.38
2024-11-26	BUY	21	11.770*	12.41
2024-11-21	BUY	105	11.270*	12.55
2024-11-20	BUY	63	11.310*	12.62
2024-11-18	BUY	252	11.880*	12.73
2024-11-12	BUY	168	13.620*	12.67
2024-11-08	BUY	105	13.880*	12.59
2024-11-07	BUY	315	13.270*	12.53
2024-11-06	BUY	42	13.250*	12.47
2024-10-31	BUY	21	12.360*	12.29

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of STOK

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	262,760	120	369,781	71.1%
2025-09-18	345,578	6,230	402,474	85.9%
2025-09-17	259,773	0	416,703	62.3%
2025-09-16	82,952	0	261,951	31.7%
2025-09-15	127,587	993	276,305	46.2%
2025-09-12	255,262	3,603	365,375	69.9%
2025-09-11	300,167	8,555	440,705	68.1%
2025-09-10	353,400	0	484,109	73.0%
2025-09-09	183,646	100	292,153	62.9%
2025-09-08	329,798	0	585,233	56.4%
2025-09-05	98,134	10	194,324	50.5%
2025-09-04	122,399	505	235,777	51.9%
2025-09-03	222,505	23	315,410	70.5%
2025-09-02	258,382	703	412,066	62.7%
2025-08-29	160,764	424	219,706	73.2%
2025-08-28	149,055	0	220,197	67.7%
2025-08-27	116,276	13,373	208,155	55.9%
2025-08-26	389,100	479	772,802	50.3%
2025-08-25	120,687	1,219	207,751	58.1%
2025-08-22	132,525	7,377	305,663	43.4%
2025-08-21	183,477	0	320,429	57.3%
2025-08-20	177,477	1,472	319,663	55.5%
2025-08-19	233,847	443	570,003	41.0%
2025-08-18	266,157	2,972	393,813	67.6%
2025-08-15	325,620	13,531	744,113	43.8%
2025-08-14	465,564	1,736	679,942	68.5%
2025-08-13	689,376	127	1,184,978	58.2%
2025-08-12	91,216	0	155,563	58.6%
2025-08-11	66,965	39	112,390	59.6%
2025-08-08	82,362	0	126,449	65.1%
2025-08-07	87,291	21	136,049	64.2%
2025-08-06	212,281	190	318,905	66.6%
2025-08-05	89,249	0	120,250	74.2%
2025-08-04	100,923	0	144,550	69.8%
2025-08-01	87,655	0	133,696	65.6%
2025-07-31	101,691	0	146,686	69.3%
2025-07-30	87,857	0	136,030	64.6%
2025-07-29	120,439	100	375,067	32.1%
2025-07-28	151,571	3,048	240,590	63.0%
2025-07-25	168,182	1,866	331,958	50.7%
2025-07-24	248,649	116	499,350	49.8%
2025-07-23	401,884	19	652,146	61.6%
2025-07-22	581,247	292	1,255,404	46.3%
2025-07-21	177,262	0	270,205	65.6%
2025-07-18	428,131	0	678,550	63.1%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE